Vertex Pharmaceuticals, Inc. (VRTX) Misses Q1 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts VRTX Hot Sheet
Price: $523.93 -2.1%
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +10.7%
Financial Fact:
Research and development expenses: 272.37M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Vertex Pharmaceuticals, Inc. (NASDAQ: VRTX) reported Q1 EPS of $0.55, $0.11 worse than the analyst estimate of $0.66. Revenue for the quarter came in at $438.7 million versus the consensus estimate of $473.37 million.
Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Vertex Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on Vertex Pharmaceuticals, Inc. (VRTX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- Caldwell sells IQTalent subsidiary to WinMil for C$4.7M
- AI-powered cyber threats light a fire under cybersecurity stocks
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
